Microfluidic affinity profiling reveals a broad range of target affinities for anti-SARS-CoV-2 antibodies in plasma of Covid survivors

Published on September 23rd, 2020

Authors: Matthias M. Schneider, Marc Emmenegger, Catherine K. Xu, Itzel Condado Morales, Priscilla Turelli, Manuela R. Zimmermann, Beat M. Frey, Sebastian Fiedler, Viola Denninger, Georg Meisl, Vasilis Kosmoliaptsis, Heike Fiegler, Didier Trono, Tuomas P. J. Knowles, and Adriano Aguzzi

medRxiv, 2020, 20196907. DOI: 10.1101/2020.09.20.20196907


The clinical outcome of SARS-CoV-2 infections can range from asymptomatic to lethal, and is thought to be crucially shaped by the quality of the immune response which includes antibody titres and affinity for their targets. Using Microfluidic Antibody Affinity Profiling (MAAP), Schneider et al. determined the aggregate affinities and concentrations of anti-SARS-CoV-2 antibodies in plasma samples of 42 seropositive individuals, 23 of whom were confirmed to be SARS-CoV-2-positive by PCR testing. They found that dissociation constants (KD) of anti-RBD antibodies spanned more than two orders of magnitude from 80 pM to 25 nM, despite having similar antibody concentrations. The tested individuals showed progressively higher antibody concentrations but constant KD values, suggesting that affinities did not mature over time. 33 sera showed affinities higher than that of the CoV2 spike for its ACE2 receptor.

Accordingly, addition of seropositive plasma to pre-formed spike-ACE2 receptor complexes led to their dissociation. Finally, they observed that the RBD of HKU1, OC43, and SARS-CoV coronaviruses, but not unrelated control proteins, were able to compete substantially with the RBD of SARS-CoV-2 in solution.

Therefore, the affinity of total plasma immunoglobulins to SARS-CoV-2 is an indicator of the quality of the immune response to SARS-CoV-2, and may help select the most efficacious samples for therapeutic plasmapheresis.

InstrumentFluidity One-W Serum
Therapeutic areaCOVID

A full list of recent publications in which our technology has been applied can be accessed here.